ClinicalTrialsFinder

Blasts More Than 5 Percent of Peripheral Blood White Cells Clinical Trials in Portland, Oregon

1 recruitingPortland, Oregon

Showing 1–1 of 1 trials

Recruiting
Phase 2

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Blasts More Than 5 Percent of Bone Marrow Nucleated CellsBCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White Cells+2 more
William Shomali10 enrolled4 locationsNCT03801434